This Webinar will focus on evidence that sodium-glucose-linked cotransport inhibitors (SGLT2i) reduces the development of end-stage kidney disease (ESKD), cardiovascular events, including heart failure and cardiac death in diabetic and non-diabetic patients, with and without chronic kidney disease. This webinar is proudly sponsored by AstraZeneca.
Patients with diabetic and non-diabetic chronic kidney disease (CKD) have a high risk of cardiovascular events, reaching end-stage kidney disease (ESKD) and premature death. Blockade of the renin-angiotensin system was shown almost 20 years ago to reduce the risk of ESKD by 16-20%, but until very recently there have been no strategies that have been shown to further reduce the high cardiovascular and renal risk in these patients. Sodium-glucose-linked cotransport inhibitors (SGLT2i) have been recently shown to reduce cardiovascular and renal risk. The trials and the postulated mechanisms of action will be explored in the Webinar. The data is of relevance to all clinicians providing care to patients with CKD
Tuesday, 20 October 2020
6.30pm - 7.30pm AEDT
Click here to check your local time
Carol Pollock is Professor of Medicine at University of Sydney and based at Royal North Shore Hospital. She has authored over 375 publications in basic research and clinical medicine with over 22,800 citations in esteemed medical journals. She is an inaugural Fellow of the Australian Academy of Health and Medical Sciences (2015), was conferred a Vice Chancellors Award for Excellence in Research Supervision (2012) and recognised as a ‘Distinguished Professor’ by the University of Sydney (2012). She was the 2014 recipient of the Ministerial Award for Excellence in Cardiovascular Research. She is Chair of Kidney Health Australia, Deputy Chair of the Board of the Australian Organ, Tissue and Transplant Authority, Chair of the NSW Cardiovascular Research Network and Chair of the NSW Bureau of Health Information. She was appointed to NHMRC Council in 2018. She was Chair of the Northern Sydney Local Health District Board since its inception in 2011 till Dec 2016. She is a Director of several Biotech companies.
Your computer or mobile device
Details will be provided to registrants via email prior to the live broadcast. PS -- Make sure to check your junk or spam inbox.
RSA Members - FREE of Charge
Non-Members - AU$15.00
Not a RSA member? Join now!